エストラムスチン
参考資料

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81  “Pharmacokinetics and pharmacodynamics of estramustine phosphate”. Clin Pharmacokinet 34 (2):  163–72. (February 1998). doi:10.2165/00003088-199834020-00004. PMID 9515186.
1 2 3 4 5  “Pharmacology of estrogens and progestogens: influence of different routes of administration”. Climacteric 8 Suppl 1:  3–63. (2005). doi:10.1080/13697130500148875. PMID 16112947. http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41  “Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer”. Int. J. Urol. 8 (2):  33–6. (February 2001). doi:10.1046/j.1442-2042.2001.00254.x. PMID 11240822.
1 2 3  “Emcyt (estramustine) dosing, indications, interactions, adverse effects, and more”. Medscape Reference.   WebMD. 8 February 2014閲覧。
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25  Inoue, Takahiro (2018). “Role of Estramustine Phosphate and Other Estrogens for Castration-Resistant Prostate Cancer”. Hormone Therapy and Castration Resistance of Prostate Cancer. pp. 249–256. doi:10.1007/978-981-10-7013-6_26. ISBN 978-981-10-7012-9
1 2 3 4 5 6 7 8 9 10 11 12  “Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer”. Drugs Aging 7 (1):  49–74. (July 1995). doi:10.2165/00002512-199507010-00006. PMID 7579781.
1 2 3 4  https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018045s023lbl.pdf
1 2  “Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis”. Medicine (Baltimore) 95 (39):  e4801. (September 2016). doi:10.1097/MD.0000000000004801. PMC 5265899. PMID 27684806. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265899/.
1 2 3 4 5 6 7 8  “The use of estramustine phosphate in the modern management of advanced prostate cancer”. BJU Int. 108 (11):  1782–6. (December 2011). doi:10.1111/j.1464-410X.2011.10201.x. PMID 21756277.
1 2 3  Simpson, D; Wagstaff, AJ (2003). “Estramustine Phosphate Sodium”. American Journal of Cancer 2 (5):  373–390. doi:10.2165/00024669-200302050-00013.
↑  “Estramustine-based chemotherapy”. Semin. Urol. Oncol. 15 (1):  13–9. (February 1997). PMID 9050135.
1 2 3 4  “Estramustine revisited”. Cancer Treat. Res.. Cancer Treatment and Research 78:  163–84. (1995). doi:10.1007/978-1-4615-2007-8_8. ISBN 978-1-4613-5829-9. PMID 8595142.
1 2 3 4 5 6 7 8  Michael Oettel; Ekkehard Schillinger (6 December 2012). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 540–. ISBN 978-3-642-60107-1. https://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA540
1 2 3 4 5  “エストラサイトカプセル156.7mg 添付文書”. www.info.pmda.go.jp. 2022年1月3日閲覧。
1 2 3  “Androgens and prostate cancer: biology, pathology and hormonal therapy”. Eur. J. Cancer 33 (4):  545–54. (April 1997). doi:10.1016/S0959-8049(96)00444-3. PMID 9274433.
1 2 3 4 5 6 7   Index Nominum 2000: International Drug Directory. Taylor & Francis. (January 2000). pp. 406–407. ISBN 978-3-88763-075-1. https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA406
↑  “Estramustine Uses, Side Effects & Warnings”. 2022年1月4日閲覧。
1 2 3 4 5 6  “Estracyt Capsules - Summary of Product Characteristics (SPC)”. electronic Medicines Compendium.   Pfizer Limited (12 August 2013). 8 February 2014閲覧。
↑  Aurel Lupulescu (24 October 1990). Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 40–. ISBN 978-0-8493-5973-6. https://books.google.com/books?id=VddUa-2cp-YC&pg=PA40
1 2  Valentino Stella; Ronald Borchardt; Michael Hageman; Reza Oliyai, Hans Maag, Jefferson Tilley (12 March 2007). Prodrugs: Challenges and Rewards. Springer Science & Business Media. pp. 174–. ISBN 978-0-387-49782-2. https://books.google.com/books?id=qkjHxX5TgHEC&pg=PA174
↑  “The use of estrogen therapy in men”. Curr Opin Pharmacol 3 (6):  650–4. (2003). doi:10.1016/j.coph.2003.07.004. PMID 14644018.
1 2  “Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study”. Urology 55 (3):  328–33. (2000). doi:10.1016/s0090-4295(99)00580-4. PMID 10699602.
↑  “Estramustine phosphate for preventing flare-up in luteinizing hormone-releasing hormone analogue depot therapy”. Eur. Urol. 27 (3):  192–5. (1995). doi:10.1159/000475159. PMID 7541359.
↑  “Endocrine treatment of prostate cancer”. J. Steroid Biochem. Mol. Biol. 92 (4):  287–95. (November 2004). doi:10.1016/j.jsbmb.2004.10.005. PMID 15663992.
↑  “Estrogens in the treatment of prostate cancer”. J. Urol. 154 (6):  1991–8. (December 1995). doi:10.1016/S0022-5347(01)66670-9. PMID 7500443.
↑  “Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data”. Lancet Oncol. 8 (11):  994–1000. (2007). doi:10.1016/S1470-2045(07)70284-X. PMID 17942366.
↑  “Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer”. Clin Genitourin Cancer 13 (5):  441–6. (October 2015). doi:10.1016/j.clgc.2015.03.004. PMID 25920994.
1 2 3 4 5 6 7 8 9 10 11 12 13 14  “Clinical pharmacokinetics of estramustine phosphate”. Urology 23 (6 Suppl):  22–7. (June 1984). doi:10.1016/S0090-4295(84)80093-X. PMID 6375076.
1 2  “Estracyt in advanced carcinoma of the breast: a phase II study”. Clin Radiol 30 (2):  139–47. (March 1979). doi:10.1016/S0009-9260(79)80133-6. PMID 86404.
1 2  “Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol”. Br J Urol 55 (4):  408–12. (August 1983). doi:10.1111/j.1464-410X.1983.tb03333.x. PMID 6349745.
1 2 3 4 5 6  J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 502–503. ISBN 978-1-4757-2085-3. https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA502
1 2  “Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor”. Biochem. Pharmacol. 55 (9):  1427–33. (May 1998). doi:10.1016/S0006-2952(97)00657-6. PMID 10076535.
1 2  “Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer”. Acta Urol Belg 58 (4):  89–95. (1990). PMID 2093302.
1 2 3  “Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients”. J. Urol. 124 (2):  232–6. (August 1980). doi:10.1016/S0022-5347(17)55383-5. PMID 7190620.
↑  “Recent advances in chemotherapy for advanced prostate cancer”. Curr Urol Rep 1 (1):  48–56. (May 2000). doi:10.1007/s11934-000-0035-z. PMID 12084341.
1 2  “The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin”. Br J Urol 58 (4):  412–6. (August 1986). doi:10.1111/j.1464-410X.1986.tb09095.x. PMID 3092893.
↑  Fredholm, B., Jensen, G., Lindskog, M., & Muntzing, J. (1974, January). Effects of estramustine phosphate (Estracyt) on growth of DMBA-induced mammary tumors in rats. In Acta Pharmacologica et Toxicologica (Vol. 35, pp. 28-28). 35 Norre Sogade, PO Box 2148, DK-1016 Copenhagen, Denmark: Munksgaard Int Publ Ltd.
1 2 3  “Molecular conformation of estramustine and two analogues”. Mol. Pharmacol. 41 (3):  569–76. (March 1992). PMID 1545778. http://molpharm.aspetjournals.org/content/41/3/569.
1 2  “Estramustine phosphate sodium”. Drug Intell Clin Pharm 18 (5):  368–74. (May 1984). doi:10.1177/106002808401800502. PMID 6373212.
↑  “Estramustine--a nitrogen mustard/steroid with antimicrotubule activity”. Pharmacol. Ther. 43 (3):  299–319. (1989). doi:10.1016/0163-7258(89)90012-0. PMID 2682681.
↑  Franco Cavalli; Stan B. Kaye; Heine H Hansen; James O Armitage; Martine Piccart-Gebhart (12 September 2009). Textbook of Medical Oncology, Fourth Edition. CRC Press. pp. 442–. ISBN 978-0-203-09289-7. https://books.google.com/books?id=WdDKBQAAQBAJ&pg=PA442
↑  “The hydrolysis of estramustine phosphate; in vitro studies”. Eur J Drug Metab Pharmacokinet 8 (4):  395–402. (1983). doi:10.1007/BF03188772. PMID 6673977.
1 2  “Single nucleotide polymorphisms of 17beta-hydroxysteroid dehydrogenase type 7 gene: mechanism of estramustine-related adverse reactions?”. Int. J. Urol. 16 (10):  836–41. (October 2009). doi:10.1111/j.1442-2042.2009.02374.x. PMID 19735314.
1 2  “Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients”. Int. J. Urol. 12 (2):  166–72. (February 2005). doi:10.1111/j.1442-2042.2005.01004.x. PMID 15733111.
↑  Gate, Laurent; Tew, Kenneth D. (2011). “Alkylating Agents”. Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. pp. 61–85. doi:10.1007/978-90-481-9704-0_4. ISBN 978-90-481-9703-3
↑  http://www.ilexmedical.com/files/PDF/Estradiol_ARC.pdf
↑  Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 245, 454. ISBN 978-3-7692-2114-5. https://books.google.com/books?id=2HBPHmclMWIC&pg=PA245
↑  Thorsteinn Loftsson (25 January 2014). Drug Stability for Pharmaceutical Scientists. Academic Press. pp. 77–. ISBN 978-0-12-411562-0. https://books.google.com/books?id=dUzyAQAAQBAJ&pg=PA77
↑  S. Bernal (21 August 1997). Drug Resistance in Oncology. CRC Press. pp. 287–. ISBN 978-1-4200-0209-6. https://books.google.com/books?id=x9rL5HiTFTUC&pg=PA287
↑  Samuel J. Murff (20 February 2012). Safety and Health Handbook for Cytotoxic Drugs. Government Institutes. pp. 89–. ISBN 978-1-60590-705-5. https://books.google.com/books?id=CqIPtcoUiMMC&pg=PA89
↑  William D. Figg; Cindy H. Chau; Eric J. Small (14 September 2010). Drug Management of Prostate Cancer. Springer Science & Business Media. pp. 402–. ISBN 978-1-60327-829-4. https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA402
↑  “エストラサイトカプセル156.7mg インタビューフォーム”. www.info.pmda.go.jp. 2022年1月6日閲覧。